3. GOOD HEALTH AND WELL-BEING

GSK (LON:GSK) Rating Reiterated by Citigroup – Defense World

Written by Amanda

GSK (LON:GSKGet Rating)‘s stock had its “neutral” rating reiterated by investment analysts at Citigroup in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They presently have a GBX 1,975 ($23.61) price target on the stock. Citigroup’s price target would indicate a potential upside of 13.30% from the stock’s previous close.

GSK has been the topic of several other research reports. Credit Suisse Group set a GBX 1,630 ($19.49) price target on shares of GSK in a report on Thursday. Berenberg Bank increased their price objective on shares of GSK from GBX 1,850 ($22.12) to GBX 1,950 ($23.31) and gave the company a “buy” rating in a research report on Thursday. JPMorgan Chase & Co. set a GBX 1,900 ($22.71) price objective on shares of GSK in a research report on Wednesday. Shore Capital reaffirmed a “not rated” rating on shares of GSK in a research report on Thursday, July 14th. Finally, UBS Group set a GBX 1,850 ($22.12) price objective on shares of GSK in a research report on Wednesday. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of GBX 1,820.77 ($21.77).

GSK Trading Down 0.2 %

LON GSK opened at GBX 1,743.20 ($20.84) on Thursday. GSK has a one year low of GBX 1,224.78 ($14.64) and a one year high of GBX 2,746.59 ($32.83). The company’s 50 day moving average price is GBX 1,736.27 and its 200 day moving average price is GBX 1,682.46. The company has a debt-to-equity ratio of 147.36, a quick ratio of 0.94 and a current ratio of 1.19. The firm has a market capitalization of £70.90 billion and a price-to-earnings ratio of 1,383.49.

Insider Transactions at GSK

In related news, insider Manvinder Singh Banga purchased 647 shares of the firm’s stock in a transaction dated Thursday, June 23rd. The stock was acquired at an average price of GBX 1,691 ($20.22) per share, with a total value of £10,940.77 ($13,079.22).

About GSK

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Stories

Receive News & Ratings for GSK Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GSK and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai